Thank You!
Thank you for your email subscription. Check your email to get Coupon Code.
Marketing Strategy for Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug
Posted by Addison on Mar-29-2023
Introduction
The report primarily focuses on the marketing strategy of Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug to give a reader an overview of the growth dynamics of the company. Recently, several strategic issues and managerial problems have been identified in marketing strategy of Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug that have drawn the attention of the entire management to devise new marketing strategies that can help the company to resolve the problems to continue its expansion and future growth to achieve a competitive edge in the marketplace. This report is written to provide Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug marketing strategy with the required strategic solutions using multiple frameworks and tools.
External Environmental Analysis
PESTLE Analysis is the most popular strategic tool that is used by many organizations when conducting an external environmental analysis. This framework typically focuses on political, economic, social, technological, legal, and environmental factors that can impact the macro environment of the business (Zalengera, E.Blanchard, & C.Eames, 2014).
Political factors
Political Stability
Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug operates in a politically stable environment, which means that it provides the company with more friendly and stable business growth opportunities (Christodoulou & Cullinane, 2019). However, since Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug operates in multiple countries, there are high chances of various political tensions that can cause instability in market growth trends for Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug. This can limit the company's growth opportunities.
Pressure Groups
Moreover, it is important for Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug to analyze and monitor the activities of pressure groups. Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug can create a close collaboration with these groups to achieve long-term goals.
Corruption and Changing Policies
Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug must keep a close check on the changes in any government policies because they can directly impact the performance of the business. The operations of Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug are its different countries can become unpredictable if there is a high level of corruption and weak enforcement of the law (Achinas, Horjus, & Achinas, 2019).
Trade and Taxes
The profitability of a company is directly influenced if there are high taxes in a country. Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug should look into the taxation policies in each country before further expanding its operations (Eierle, Hartlieb, & C. Hay, 2022). Similarly, if there are high trade restrictions, it can get difficult for Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug to import and export its products, impacting the relationships with trade partners.
Economic factors
GDP, Employment, and Exchange Rates
The long-term growth strategies of Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug are majorly determined by the GDP growth of the economy. The purchasing power of consumers significantly increases with a high GDP. High unemployment in an economy shows that Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug can benefit from surplus labor with low-cost wages. Furthermore, Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug should monitor interest rates as it can affect the borrowing ability. With that being said, if there is a high fluctuation in currency, the profitability of Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug can also be influenced (Sadeghi, 2020).
Labor Market
It is important for Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug to make appropriate predictions regarding the labor market conditions in a specific economy (Sadeghi, 2020). This can help the company to hire a more talented workforce that can improve the performance of the company.
Industry lifecycle stage
Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug should consider expanding its operations in growing economies to benefit from growth opportunities. It can be challenging for Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug to enter a mature industry at a growing stage (Villamarín & Pinzon, 2017).
Social factors
Demographics
Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug should study the changing patterns of demographics, such as socio-economic variables, the aging population, and trends in migration (Barbara & Cortis, 2017). This can help the company to identify the right segment to target with a high potential for growth opportunities.
Cultural norms
Every country and society has a distinctive culture with different norms and values. It is important for Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug to study and identify social class stratification.
E-commerce
There has been a significant shift in online shopping. Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug needs to adopt necessary changes considering the growing use of social media networking sites and mobile phones to increase its revenue and overall profitability (Villamarín & Pinzon, 2017).
Technological factors
Technological innovations
On-going technological innovations should be considered carefully by Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug so that it can stay ahead of the competitive market. Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug should continue working on introducing major technological transformations to achieve a competitive advantage (Rastogi & TRIVEDI, 2016).
Social Media Marketing
The collaboration with consumers has been growing rapidly because of the development of communication technologies (Rastogi & TRIVEDI, 2016). Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug can take it as a great opportunity where can use innovative strategies to expand its customer base.
Environmental factors
Waste Management
Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug should implement the latest technological tools to minimize environmental pollution. Waste management is now getting popular and has been considered a major business norm (Igliński, Iglińska, & Cichosz, 2016).
Climatic Conditions and Eco-friendly products
Climatic conditions can influence the efficiency of Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug. The cost of a company's operations can be increased if there are extreme weather conditions. Similarly, there has been an increasing demand for eco-friendly products. Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug should work towards adopting more sustainable business practices to gain customer trust (Barkauskas, Barkauskienė, & Jasinskas, 2015).
Legal factors
Employee protection laws
It is important for Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug to follow the health and safety laws for its employees that are issued by the authorities to ensure the safety of its labor.
Consumer laws
Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug should protect its customer data to ensure their security and privacy concerns. Moreover, it should set the right price with the right product quality (Igliński, Iglińska, & Cichosz, 2016).
Porter's Five Forces
Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug can use Porter's Five Forces to analyze the competitive landscape of the industry. The strategic planners of Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug can use this framework to make effective decisions.
Threat of New Entrants
Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug operates in an industry where it is difficult to achieve economies of scale, making it difficult for new entrants to enter the industry (Yunna & Yisheng, 2014). There is a strong product differentiation with high capital requirements. Moreover, it is difficult to establish a distribution network easily in this industry. Thus, Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug has a weak threat of new entrants.
Bargaining Power of Suppliers
There are more suppliers in the industry of Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug. This shows that there is less control over prices. Organizations like Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug can easily switch to other suppliers because of less differentiation in products. This makes the bargaining power of suppliers a weak force in Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug's industry (H. Th. Bruijl, 2018).
Bargaining Power of Buyers
The industry in which Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug operates has many suppliers as companies to buyers. This means that buyers have fewer options and do not have control over prices (H. Th. Bruijl, 2018). The high product differentiation shows that there are few alternative products for buyers, and there is a high switching cost. This makes the bargaining power of buyers a weak force in the industry.
Threat of Substitute Products and Services
Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug operates in an industry that offers very few substitutes to its customers. The substitutes that are available are expensive because of their high quality (Zhao, Zuo, & Wu, 2016). However, companies like Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug sell their products at a lower prices. This clearly shows that buyers may feel reluctant when switching to other substitutes.
Rivalry Among Existing Firms
Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug operates in a less competitive industry. The already established companies have a large market share, meaning that any move by the existing companies will be noticed. Moreover, Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug has to take several competitive actions to become a market leader, as the industry is likely to grow rapidly in the coming years (Aithal, 2020).
SWOT Analysis
Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug can make use of SWOT analysis to effectively analyze the company's internal strengths, weaknesses, external opportunities, and threats.
Strengths
Strong distribution network
Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug operates in various countries and has multiple outlets that help the company to deliver its products quickly to its customers. This shows that Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug has a strong distribution network (Benzaghta, Elwalda, & Mousa, 2021).
Financial position
Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug has established itself as a strong financial company over the past few years. It has generated enough profits that can be used to finance any future expenditure (Basset & Mohamed, 2018).
Automation
Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug has adopted the latest and innovative technology in its business operations, which has allowed the company to reduce its production costs (Benzaghta, Elwalda, & Mousa, 2021).
Social media presence
Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug has been successful in establishing itself as a strong brand on social media platforms that, includes Facebook, Twitter, and Instagram. This increases customer engagement (Basset & Mohamed, 2018).
Weaknesses
High rent costs
Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug has its manufacturing plants on rented properties. This increases the company's overall costs, and a significant portion of Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug's profits go into paying the rent (Comino & Ferretti, 2016).
Research and Development
Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug has not been able to conduct effective and in-depth market research regarding new markets and products (Comino & Ferretti, 2016). Customer trends are always evolving, and it is important for Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug to take immediate action in conducting its research.
Centralized Power
There has been a centralized decision-making process in Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug. This means that employees have to consult their managers before taking any decision themselves. This slow down the decision-making process. and employees feel demotivated. Thus, impacting the operations of Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug (Comino & Ferretti, 2016).
Opportunities
Presence of Internet
Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug has a great opportunity of expanding its business by using the internet. Since there has been a growing trend in online shopping Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug can boost its sales by expanding its online stores (Yan, Xia, & X.H.Bao, 2015). Additionally, social media platforms can be updated constantly to engage customers with all the new products introduced by Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug.
Technological Innovations
Technology is constantly evolving, and Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug can benefit from it by implementing the technology in its various departments. Manufacturing process can be completed automated, which can eventually help Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug to reduce its costs (Taghavifard, Mahdiraji, & Alibakhshi, 2018).
Globalization
The continuous increase in globalization has allowed Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug to expand its business operations across borders. It has the opportunity of entering new markets (Yan, Xia, & X.H.Bao, 2015).
Threats
New Entrants
Recently, many companies are entering the industry in which Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug operates. This means that there are chances of increased competition. This poses a threat to Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug as it has to put more effort into gaining market share (Taghavifard, Mahdiraji, & Alibakhshi, 2018).
Fluctuations in exchange rates
The exchange rates are highly subjected to fluctuations that negatively impact the sales of Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug. Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug needs to study the changing fluctuations to keep up with its profitability (Vlados & Chatzinikolaou, 2019).
Consumer trends
The consumer trends are constantly changing, that causes changes in their demands. This puts pressure on companies like Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug, who have to continuously meet their consumer demands. Moreover, there is a significant threat from substitute products because consumers tend to switch to these companies (Vlados & Chatzinikolaou, 2019).
Marketing Mix
Product
Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug operates in a wider range of products. Each of the products has its further product lines that are sold under the Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug. This means that customers can benefit from a large variety of products. Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug sells highly differentiated products with higher quality that, gives it a competitive edge (Khan, 2014).
Price
Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug follows a competitive pricing strategy. The company also takes into account all its costs before setting its prices (Londhe, 2014). Currently, Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug is using a product bundle pricing strategy where customers get bundled products at lower prices.
Place
Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug has adopted various distribution channels to reach its customers. The company sells its products through its website directly (Thabit & Raewf, 2018). Apart from this, it also distributes its products to wholesalers, who then further sell it to small retailers. Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug has its own retail stores where it sells its products directly to consumers.
Promotion
Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug uses traditional and modern promotional techniques. TV ads are used to reach a larger audience. Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug also advertises on social media sites such as Facebook, Instagram, and Twitter. Events are sponsored by the company. Moreover, Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug participates in several exhibitions (Londhe, 2014).
VRIO Analysis
Valuable
Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug engages in corporate social responsibility activities. This has allowed the company to establish a strong brand image. Since, Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug has a well-established distribution network, the products are reached to consumers in a timely manner. Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug has been able to introduce innovation in its various departments, which has lowered its costs (Ariyani & Daryanto, 2018).
Rare
Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug operates in multiple countries. This means that its global presence is a rare factor. It works towards an organizational culture that encourages teamwork, and creativity among employees (Ariyani & Daryanto, 2018). Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug is also able to adapt to different societies, and cultures due to its exposure to various locations.
Inimitable
The products produced by Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug are of a high quality. Customers make repetitive purchases, and thus it is an inimitable source. (Miethlich & G. Oldenburg, 2019). Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug has a significant placement of its stores that gives an easy access to its customers. Additionally, the company has been using a competitive pricing strategy because it has been able to achieve economies of scale, thus lower production costs.
Organization
Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug, over the years, has successfully gained a financial strength. Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug can make use of these finances to invest in major acquisitions that give it more growth opportunities. The advancements in technology have allowed Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug to manage its operations more effectively. Distribution channels are another resource for Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug. The supply chain is very efficient, resulting in more revenue (Miethlich & G. Oldenburg, 2019).
Value Chain Analysis
Primary Activities
Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug is involved in primary activities such as the production of goods and then selling them to the target audience.
Inbound Logistics
Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug should ensure to have a strong relationship with its suppliers to avoid any inconvenience in receiving, storing, and distributing the product. This will help Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug to have a more effective transformation of a product (Ariwibowo & Saputro, 2021).
Operations
Operations involves manufacturing as well as services. Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug should conduct an in-depth analysis of its operational activities to remain ahead of its competitors (M.El-Sayed, W.Dickson, & O.El-Naggar, 2015). This will increase the productivity of the company, and more profits can be generated.
Outbound Logistics
It is important for Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug to analyze, and optimize its outbound logistics so that it is able to achieve the long-term corporate goals. Managing outbound activities properly reduces the chance of late deliveries (M.El-Sayed, W.Dickson, & O.El-Naggar, 2015).
Marketing and Sales
Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug should use various marketing and sales techniques to differentiate its products from its competitors. Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug can adopt marketing and sales activities such as promotional activities, advertising, and building strong relationships with suppliers and customers (Ariwibowo & Saputro, 2021).
Services
In terms of services, Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug must ensure that it provides its customers with the pre-sale and post-sale services (Jaligot, C.Wilson, & R.Cheeseman, 2016). The post-sale service typically falls into the promotional activities of a company. Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug can thus develop its customer loyalty.
Secondary Activities
Firm infrastructure
A strong infrastructure of a firm can enable Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug to optimize the entire value chain of the company. Moreover, by controlling the infrastructure activities, Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug can be in a better position to get a strong foothold in the competitive marketplace (Darmawan & Wiguna, 2014).
Human Resource Management
Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug should place its major focus on analyzing the different aspects of HR, such as recruitment, selection, training, and performance evaluation of employees (Darmawan & Wiguna, 2014). Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug can reduce its costs by identifying and analyzing the costs associated with hiring and training.
Procurement
Procurement is an important element in the Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug's value chain. It is important for the company to assess its overall procurement activities so that the inbound, outbound, and operational activities can be optimized (Kumar & P. V., 2016).
Ansoff's Matrix
Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug can implement Ansoff's Matrix to make decisions regarding its business growth. This framework includes four different strategic choices that can be selected by Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug.
Market Penetration
Production capacity
Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug can increase its overall production capacity. This will allow the company to reach more wider audience in an existing market. Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug can also benefit from the reduced costs by expanding its production capacity. Thus, Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug can attract more customers using competitive pricing (Madsen, 2017).
Marketing Investment
Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug can penetrate the market by investing more in marketing and sales activities. This will help the company to engage with its customer more effectively, leading to more potential customers (Dawes, 2020).
Distribution Channels
Innovative and unique distribution channels can be explored by Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug. This will enable the company to reach new segments and groups of customers (Dawes, 2020). In addition to this, Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug can penetrate the market by improving its supply chain, giving more accessibility to customers.
Joint Ventures/Acquisitions
Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug can enter into joint ventures or can take over other leading companies of the market. This will give Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug more market share.
Market Development
Research & Development
Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug should keep on investing in its R&D department, so it is able to identify the changing trends of the market. This will help Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug to target the right market at the right time (Mukangai & Murigi, 2021).
Expanding Regionally
Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug can enter in a new market by expanding its operations regionally. This includes considering different cities of the country. Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug must consider any cultural differences when entering a new market (Mukangai & Murigi, 2021).
New Segments
New segments of the current market can be explored (Mukangai & Murigi, 2021). Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug can add new features and product uses to its existing products that satisfies the needs of a different customer segment.
Product Development
Modifications
Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug can modify the existing product by improving its features to enhance the product offerings.
Launching additional products
Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug should invest in its R&D department so it can come up with new and innovative products that attracts and fulfill the needs of the target audience. This will boost the sales of Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug and will increase profitability (Khajezadeh, Niasar, & Asli, 2019).
Diversification
Vertical Integration
Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug can consider vertical integration. This will allow Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug to develop and launch new products that are similar to its existing product category (Khajezadeh, Niasar, & Asli, 2019).
Horizontal Integration
Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug can diversify its business operation using horizontal integration. This means that the new products and services of Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug will not be related to its current products (Dhir & Dhir, 2015).
A new business diversification
Entering into a completely new business can be considered by Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug. The organization can work towards starting a new business that can give a company more growth prospects in the future (Dhir & Dhir, 2015). Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug can conglomerate with the help of mergers and acquisitions.
Conclusion
To conclude, it could be said that Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug can resolve its current managerial and strategic problems by focusing on its existing products. The company can adopt more attractive marketing strategies that can help Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug to boost its revenue and profitability. It is recommended to focus on maintaining strong supplier relationships. Moreover, it is also advised to focus on more innovative products so Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug can remain competitive in the market.
References
Achinas, S., Horjus, J., & Achinas, V. (2019). A PESTLE Analysis of Biofuels Energy Industry in Europe. Sustainability, 11(24), 5981.
Aithal, P. S. (2020). Study on Amgen Inc s Epogen--Commercializing the First Biotech Blockbuster Drug Analysis Technique for Business Models, Business Strategies, Operating Concepts & Business Systems. International Journal in Management and Social Science, 95-115.
Ariwibowo, P., & Saputro, F. B. (2021). Analysis of Strength & Weakness, Using the Concept of Resource-Based View with the VRIO Framework in Sharia Cooperatives. Jurnal Manajemen Strategi Dan Aplikasi Bisnis, 279 - 294.
Ariyani, W., & Daryanto, A. (2018). Operationalization of Internal Analysis Using the VRIO Framework: Development of Scale for Resource and Capabilities Organization (Case Study: XYZ Company Animal Feed Business Unit). Asian Business Research Journal, 9–14.
Barbara, C., & Cortis, D. (2017). The European Insurance Industry: A PEST Analysis. International Journal of Financial Studies, 5(2), 14.
Barkauskas, V., Barkauskienė, K., & Jasinskas, E. (2015). Analysis of Macro Environmental Factors Influencing the Development of Rural Tourism: Lithuanian Case. Procedia - Social and Behavioral Sciences, 167-172.
Basset, M. A., & Mohamed, M. (2018). An Extension of Neutrosophic AHP–SWOT Analysis for Strategic Planning and Decision-Making. Symmetry, 10(4), 18.
Benzaghta, ,. M., Elwalda, A., & Mousa, M. M. (2021). SWOT analysis applications: An integr T analysis applications: An integrative literature review. Journal of Global Business Insights, 55-73.
Christodoulou, A., & Cullinane, K. (2019). Identifying the Main Opportunities and Challenges from the Implementation of a Port Energy Management System: A SWOT/PESTLE Analysis. Sustainability, 11(21), 6046.
Comino, E., & Ferretti, V. (2016). Indicators-based spatial SWOT analysis: Supporting the strategic planning and management of complex territorial systems. Ecological Indicators, 1104-1117.
Darmawan, M. A., & Wiguna, B. (2014). Value chain analysis for green productivity improvement in the natural rubber supply chain: a case study. Journal of Cleaner Production, 201-211.
Dawes, J. (2020). The Ansoff Matrix: A Legendary Tool, But with Two Logical Problems. SSRN.
Dhir, S., & Dhir, S. (2015). Diversification: Literature Review and Issues. Wiley Online Library.
Eierle, B., Hartlieb, S., & C. Hay, D. (2022). External Factors and the Pricing of Audit Services: A Systematic Review of the Archival Literature Using a PESTLE Analysis. A Journal of Practice & Theory, 95–119.
H. Th. Bruijl, D. G. (2018). The Relevance of Porter's Five Forces in Today's Innovative and Changing Business Environment. SSRN.
Igliński, B., Iglińska, A., & Cichosz, M. (2016). Renewable energy production in the Łódzkie Voivodeship. The PEST analysis of the RES in the voivodeship and in Poland. Renewable and Sustainable Energy Reviews, 737-750.
Jaligot, R., C.Wilson, D., & R.Cheeseman, C. (2016). Applying value chain analysis to informal sector recycling: A case study of the Zabaleen. Resources, Conservation and Recycling, 80-91.
Khajezadeh, M., Niasar, M. S., & Asli, S. A. (2019). Application of Neural Network in Portfolio Product Companies: Integration of Boston Consulting Group Matrix and Ansoff Matrix. International Journal of Economics and Management Engineering, 13(6), 809-813.
Khan, D. M. (2014). The Concept of ‘Marketing Mix’ and its Elements. International Journal of Information, Business and Management, 16(2), 95-107.
Kumar, D., & P. V., R. (2016). Value Chain: A Conceptual Framework. International Jorunal of Engineering and Management Sciences, 74-77.
Londhe, B. (2014). Marketing Mix for Next Generation Marketing. Procedia Economics and Finance, 335-340.
M.El-Sayed, A.-F., W.Dickson, M., & O.El-Naggar, G. (2015). Value chain analysis of the aquaculture feed sector in Egypt. Aquaculture, 92-101.
Madsen, D. Ø. (2017). Not Dead Yet: The Rise, Fall and Persistence of the BCG Matrix. Problems and Perspectives in Management, 19-34 .
Miethlich, B., & G. Oldenburg, A. (2019). The Employment of Persons with Disabilities as a Strategic Asset: A Resource-Based-View using the Value-Rarity-Imitability-Organization (VRIO) Framework. Journal of Eastern Europe Research in Business and Economics, 1-13.
Mukangai, W. I., & Murigi, E. M. (2021). The Effect of Market Development on Sales Performance of Agro-Based Dealers in Nairobi City County, Kenya. Journal of Marketing and Communication, 4(1), 23-35.
Rastogi, N., & TRIVEDI, D. (2016). Pestle Technique- A Tool to Identify External Risks in Construction Projects. International Research Journal of Engineering and Technology, 3(1), 385-388.
Sadeghi, V. a. (2020). The motivational factors of business venturing: Opportunity versus necessity? A gendered perspective on European countries. Journal of Business Research, 279-289.
Taghavifard, M. T., Mahdiraji, H. A., & Alibakhshi, A. M. (2018). An Extension of Fuzzy SWOT Analysis: An Application to Information Technology. Information, 9(3), 46.
Thabit, T., & Raewf, M. (2018). The Evaluation of Marketing Mix Elements: A Case Study. International Journal of Social Sciences & Educational Studies, 4(4), 100 - 109.
Villamarín, J. M., & Pinzon, B. D. (2017). Key Success Factors to Business Intelligence Solution Implementation. Journal of Intelligence Studies in Business, 48-69.
Vlados, C., & Chatzinikolaou, D. (2019). Towards a Restructuration of the Conventional SWOT Analysis. Business and Management Studies, 76-84.
Yan, J., Xia, F., & X.H.Bao, H. (2015). Strategic planning framework for land consolidation in China: A top-level design based on SWOT analysis. Habitat International, 46-54.
Yunna, W., & Yisheng, Y. (2014). The competition situation analysis of shale gas industry in China: Applying Porter’s five forces and scenario model. Renewable and Sustainable Energy Reviews, 798-805.
Zalengera, C., E.Blanchard, R., & C.Eames, P. (2014). Overview of the Malawi energy situation and A PESTLE analysis for sustainable development of renewable energy. Renewable and Sustainable Energy Reviews, 335-347.
Zhao, Z. Y., Zuo, J., & Wu, P. H. (2016). Competitiveness assessment of the biomass power generation industry in China: A five forces model study. Renewable Energy, 144-153.
Related Article
- PESTEL Analysis of Amgen Inc s Epogen Commercializing the First Biotech Blockbuster Drug
- Hofstede Cultural Model of Amgen Inc s Epogen Commercializing the First Biotech Blockbuster Drug
- Net Present Value (NPV) Analysis of Amgen Inc s Epogen Commercializing the First Biotech Blockbuster Drug
- Marketing Mix (4Ps) Analysis of Amgen Inc s Epogen Commercializing the First Biotech Blockbuster Drug
- Corporate Social Responsibility of Amgen Inc s Epogen Commercializing the First Biotech Blockbuster Drug
- Amgen Inc s Epogen Commercializing the First Biotech Blockbuster Drug Discounted Cash Flow (DCF) Analysis
- VRIO Analysis of Amgen Inc s Epogen Commercializing the First Biotech Blockbuster Drug
- Amgen Inc s Epogen Commercializing the First Biotech Blockbuster Drug Case Solution
- Blue Ocean Strategy of Amgen Inc s Epogen Commercializing the First Biotech Blockbuster Drug
Latest Feedback
Davide Cirillo
Verified
Willing to work with you guys again. I totally recommend this service. Prices were great and delivery was on the given timeline. Thanks a lot!
Lisa Gao
Verified
Paper, delivery and deadline, everything was all right. Thanks a lot!
Kenneth Gichovi
Verified
I was so happy when I got the assignment back within eight hours. It was difficult for me to believe but that was really true. Thanks!
Alessio Gianni
Verified
Every point was perfectly described. The essay was in flawless formation and I am happy with this paper writing service. Thanks a lot!
Florent Sean
Verified
The assignment was completed perfectly and they delivered it on time. Awesome writing service!
Aron Zoltan
Verified
I want to recommend this service to you guys for the Dissertation. I obtained this project from them and well pleased with it.
Calculate the Price of Your Order
Next Article
- Crestor Marketing Strategy
- Genzyme Corp.: Strategic Challenges with Ceredase Marketing Strategy
- Takeda Pharmaceutical Company (C): The Future of Takeda Marketing Strategy
- Amgen Inc.: Pursuing Innovation and Imitation? (A) Marketing Strategy
- Orthoteks USA (C) Marketing Strategy
- Drug Eluting Stents: A Paradigm Shift in the Medical Device Industry Marketing Strategy
- American Cyanamid (B): Management's Response to the (A) Case Marketing Strategy
- Abbott Laboratories and HUMIRA: Launching a Blockbuster Drug (Condensed) Marketing Strategy
- Knowledge Creation at Eisai Co., Ltd. Marketing Strategy
- Orthoteks USA (B2) Marketing Strategy
Previuos Article
- Making the Case Marketing Strategy
- Joe Smith's Closing Analysis (B) Marketing Strategy
- Joe Smith's Closing Analysis (A), Spanish Version Marketing Strategy
- GMAC: The Pipeline Marketing Strategy
- On Writing Teaching Notes Well Marketing Strategy
- Exxon Corp.: Trouble at Valdez Marketing Strategy
- Ashland Oil, Inc.: Trouble at Floreffe (A) Marketing Strategy
- Ashland Oil, Inc.: Trouble at Floreffe (B) Marketing Strategy
- Ashland Oil, Inc.: Trouble at Floreffe (C) Marketing Strategy
- Ashland Oil, Inc.: Trouble at Floreffe (D) Marketing Strategy
Be a great writer or hire a greater one!
Academic writing has no room for errors and mistakes. If you have BIG dreams to score BIG, think out of the box and hire EssayPandas with BIG enough reputation.
Our Guarantees
- Quality assured
- Proof of no plagiarism
- Qualified writers
- Data security
- 24/7 support
- On time delivery
Interesting Fact
Most recent surveys suggest that around 76 % students try professional academic writing services at least once in their lifetime!
Order Now